Is Compounded Semaglutide Still Legal in 2026? What Clinic Owners Need to Know
A Regulatory Reality Check for Weight Loss Clinics Built on Compounded GLP-1s
The Short Answer Many Clinics Do Not Want to Hear
As of October 23, 2026, compounded semaglutide has not been banned. But the pathway that made it broadly available to weight loss clinics during the shortage years is closed, and what remains is narrow enough that it cannot support a clinic's primary business model.
If your clinic is still sourcing compounded semaglutide the way it did in 2024, the legal basis for that arrangement no longer exists. This is not a prediction about future enforcement. It is a description of the current regulatory position, published by the FDA and updated as recently as April 2026.
For the full metabolic clinic business model and where GLP-1s fit within it, see The Metabolic Weight Loss Clinic Business Opportunity. To see how our team plans a new weight loss clinic around FDA-approved product, read how we help founders open a medical weight loss clinic.
What Actually Changed, and When
The compounding boom depended entirely on shortage status. Under federal law, compounders may produce copies of a commercially available drug when that drug appears on the FDA's shortage list. Both GLP-1s were on it for years, and the compounding market grew to fill genuine unmet demand.
The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025. That removed the legal basis. The agency then set wind-down deadlines: enforcement discretion for state-licensed 503A pharmacies ended February 18, 2025 for tirzepatide and April 22, 2025 for semaglutide, and for 503B outsourcing facilities on March 19 and May 22, 2025. Compounders challenged both decisions in court; on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit affirmed the district court judgments in FDA's favor.
The FDA's compounding page, current as of April 2026, states the position plainly: tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA's drug shortage list. Both doors (shortage status and bulks list inclusion) are shut at the same time.
On April 30, 2026, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing no clinical need. As of October 23, 2026, we found no final FDA determination on the proposal. If the exclusion is finalized, outsourcing facilities could compound semaglutide, tirzepatide, or liraglutide from bulk only while that drug is on FDA's drug shortage list; liraglutide is still on that list (FDA data of October 23, 2026).
The Combination Workaround: What the FDA Actually Said
When shortage status ended, many in the industry pivoted to combination formulations. Semaglutide plus vitamin B12. Semaglutide plus glycine. Semaglutide plus L-carnitine. The argument was that adding a second active ingredient creates a different product that is no longer essentially a copy of Ozempic or Wegovy.
The FDA addressed this directly and rejected the premise. Its guidance gives semaglutide combined with vitamin B12 as its own worked example: the agency may consider such a product essentially a copy when it is given by the same route of administration and the ingredient amounts fall within 10 percent of the commercially available products' strengths.
What actually creates the exception is not the added ingredient. It is a prescriber's determination, documented on the prescription itself, that the change produces a significant difference for an identified individual patient.
As Foley & Lardner's analysis of the guidance notes, the FDA has not defined what type or amount of documentation satisfies that determination, which means the burden falls on the prescribing provider, and the standard against which it will be judged is unsettled.
There is also a volume ceiling that matters commercially. The FDA has stated it does not currently intend to act against a 503A compounder that fills four or fewer prescriptions of an essentially-a-copy product in a calendar month. Four. That number is not a foundation for a weight loss clinic's patient panel.
The Pathway Many Clinics Have Not Considered: An IRB-Governed Study
There is a structurally different route that does not depend on the essentially-a-copy analysis at all: an FDA-regulated clinical study run under an IRB-approved protocol and an investigational new drug application (IND). It is a research commitment, not a cheaper sourcing route.
Under this structure, the clinic operates as a research site under an approved protocol rather than as a retail dispenser. An IRB, such as WCG, reviews and approves the protocol, and the study operates under its continuing oversight.
Altos Consulting Group helps clients prepare both the IRB application and the IND. It is worth being direct about what it involves, because it is not a shortcut and should not be sold as one.
•A study drug cannot be promoted or sold commercially, and charging participants for it requires FDA's written authorization and is limited to direct cost
•Pricing for ACG's help with the IRB application and the IND is discussed once the scope is clear
•Approval is not guaranteed. No consulting firm can promise an IRB or FDA outcome, and applicants should plan for the possibility of a rejection or a request for substantial protocol revision
•Approval creates ongoing obligations (protocol adherence, documentation, adverse event reporting, and continuing review) that are real research duties, not paperwork formalities
The clinics best suited to this pathway are those genuinely prepared to operate as a research site. A clinic looking for a label to put on business as usual is not a good candidate, and the obligations that follow approval will make that obvious quickly.
What This Means for Your Clinic's Model
The strategic read is straightforward. A weight loss clinic whose margin depends on cheap compounded semaglutide is exposed, and the exposure is increasing rather than stabilizing. Clinics have three realistic responses: source FDA-approved branded product and compete on clinical depth rather than price, pursue the IRB pathway if genuinely prepared for research obligations (a study drug cannot be promoted or sold commercially), or build a metabolic health model where GLP-1s are one component rather than the entire business.
Many durable clinics are doing some combination of the first and third. For the supply side, see our guide on how to source GLP-1s for your clinic legally. For founders who have not opened yet, sourcing decisions belong in a new clinic's compliance planning, which our launch program covers. To discuss which structure fits your clinic, book a free 30-minute strategy call.
Frequently Asked Questions
Is compounded semaglutide illegal now?
Not categorically. As of October 23, 2026, it remains legal in narrow, patient-specific circumstances under 503A when a prescriber documents on the prescription that a change produces a significant difference for that individual patient. Separately, the FDA has indicated it does not currently intend to act against a 503A compounder that fills four or fewer prescriptions of an essentially-a-copy product in a calendar month. What ended was the broad, shortage-based access that supported high-volume clinic programs.
Does adding B12 or another ingredient make compounded semaglutide legal?
Not on its own. The FDA gave semaglutide plus B12 as its explicit example of a combination it may consider essentially a copy when the route of administration matches and strengths are within 10 percent of the approved products. The exception depends on a documented prescriber determination of significant difference for an individual patient, not on the presence of an additional ingredient.
How does the IRB study pathway differ from ordinary compounding?
It changes the legal frame entirely. Rather than dispensing a compounded copy of a commercially available drug, the clinic operates as a site in an FDA-regulated clinical study run under an IRB-approved protocol and an investigational new drug application (IND). That brings genuine research obligations (protocol adherence, documentation standards, adverse event reporting, and continuing review), and it requires an IRB application and an IND, with no guaranteed approval. A study drug cannot be promoted or sold commercially, and charging participants for it requires FDA's written authorization and is limited to direct cost.
What happens if the FDA finalizes the 503B bulks list exclusion?
If the exclusion is finalized, outsourcing facilities could compound semaglutide, tirzepatide, or liraglutide from bulk only while that drug is on FDA's drug shortage list; liraglutide is still on that list (FDA data of October 23, 2026). Semaglutide and tirzepatide appear on neither the 503B bulks list nor FDA's drug shortage list (FDA's compounding page, current as of April 2026), so outsourcing facilities cannot compound them from bulk now. Clinics relying on 503B-sourced liraglutide should plan for that supply to end when its shortage does, rather than waiting for a final rule.
